GlassScriptPhysician profile
Niket Nathani
NPI 1801113154
$1,357.51
in general payments reported to CMS, 2019-2025
16 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $54.01 · 2021: $52.78 · 2022: $91.63 · 2023: $280 · 2024: $350 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598 · Consulting Fee: $225 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.78 |
| Consulting Fee | $225.00 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $254.86 | 2020-2025 | Fasenra |
| Inari Medical, INC. | $249.47 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ambu A/S | $225.00 | 2024 | |
| Genentech, INC. | $150.01 | 2019 | |
| Veran Medical Technologies, INC. | $113.58 | 2019 | |
| Genzyme Corporation | $110.98 | 2024-2025 | |
| Amgen INC. | $58.51 | 2025 | Tezspire |
| Masimo Corporation | $41.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.11 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.36 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.00 | 2022 | |
| Genentech USA, INC. | $15.80 | 2020 | |
| Vertos Medical, INC. | $13.92 | 2024 | Mild Device Kit |
| Regeneron Healthcare Solutions, INC. | $13.82 | 2025 | Dupixent |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niket Nathani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.